@article{c80fa07ba3a04d759467b51dec56d5e4,
title = "B cells promote CD8 T cell primary and memory responses to subunit vaccines",
abstract = "The relationship between B cells and CD4 T cells has been carefully studied, revealing a collaborative effort in which B cells promote the activation, differentiation, and expansion of CD4 T cells while the so-called “helper” cells provide signals to B cells, influencing their class switching and fate. Interactions between B cells and CD8 T cells are not as well studied, although CD8 T cells exhibit an accelerated contraction after certain infections in B-cell-deficient mice. Here, we find that B cells significantly enhance primary CD8 T cell responses after vaccination. Moreover, memory CD8 numbers and function are impaired in B-cell-deficient animals, leading to increased susceptibility to bacterial challenge. We also show that interleukin-27 production by B cells contributes to their impact on primary, but not memory, CD8 responses. Better understanding of the interactions between CD8 T cells and B cells may aid in the design of more effective future vaccine strategies.",
keywords = "B cell cross presentation, B cell depletion, B cell help, CD8 T cell B cell interactions, common variable immunodeficiency, IL-27, MD4 mice, subunit vaccine",
author = "Jared Klarquist and Cross, {Eric W.} and Thompson, {Scott B.} and Benjamin Willett and Aldridge, {Daniel L.} and Caffrey-Carr, {Alayna K.} and Zhenming Xu and Hunter, {Christopher A.} and Andrew Getahun and Kedl, {Ross M.}",
note = "Funding Information: We would like to thank Divij Mathew, Raul Torres, Roberta Pelanda, and John Cambier for helpful discussions. We thank Jing Wang, Claudia Jakubzick, and Larry Pease for providing mouse strains necessary for these studies. We thank Cody Rester and Trevor Blain for technical assistance. We also thank Tem Morrison, Lori Sherman, and the CU Cancer Center Cell Technologies Shared Resource for producing SARS-CoV-2 spike-derived RBD protein. This work was supported by National Institute of Allergy and Infectious Diseases training grant AI074491 (to J.K.) and grants AI066121 , AI148919 , and AI126899 (to R.M.K.). Funding Information: We would like to thank Divij Mathew, Raul Torres, Roberta Pelanda, and John Cambier for helpful discussions. We thank Jing Wang, Claudia Jakubzick, and Larry Pease for providing mouse strains necessary for these studies. We thank Cody Rester and Trevor Blain for technical assistance. We also thank Tem Morrison, Lori Sherman, and the CU Cancer Center Cell Technologies Shared Resource for producing SARS-CoV-2 spike-derived RBD protein. This work was supported by National Institute of Allergy and Infectious Diseases training grant AI074491 (to J.K.) and grants AI066121, AI148919, and AI126899 (to R.M.K.). Research conceptualization: J.K. E.W.C. Z.X. C.A.H. A.G. and R.M.K. Performed research: J.K. E.W.C. S.B.T. B.W. D.L.A. A.K.C.-C. A.G. and R.M.K. Data analysis: J.K. and R.M.K. Statistical analysis: J.K. and R.M.K. Writing: J.K. and R.M.K. R.M.K. is a founder of ImmuRx Inc. a vaccine company for which intellectual property is based on the combined TLR agonist/anti-CD40 immunization platform. All other authors declare no competing interests. Publisher Copyright: {\textcopyright} 2021 The Authors",
year = "2021",
month = aug,
day = "24",
doi = "10.1016/j.celrep.2021.109591",
language = "English (US)",
volume = "36",
journal = "Cell Reports",
issn = "2211-1247",
publisher = "Cell Press",
number = "8",
}